SEC Form 4 · accession 0001562180-17-001605
WEST PHARMACEUTICAL SERVICES INC · WST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Malone
Officer — Vice President & Controller
Period of report
May 2, 2017
Accepted (ET)
May 2, 2017 · 11:24 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000105770
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 2, 2017 | M | 4,124 | $20.85 | A | 33,144 | D | |
| Common StockF2 | May 2, 2017 | S | 4,124 | $93.3114 | D | 29,020 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy) | $20.85 | May 2, 2017 | M | 4,124 | D | Feb 26, 2009 | Feb 26, 2018 | Common Stock | 4,124 | 0 | D |
Explanation of responses
- F1Reflects additional shares purchased through dividend reinvestments based on most recent plan statement.
- F2The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $93.01 to $93.43, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.